Katharina Simone Götze


Ontology type: schema:Person     


Person Info

NAME

Katharina Simone

SURNAME

Götze

Publications in SciGraph latest 50 shown

  • 2022-04-01 Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis in ANNALS OF HEMATOLOGY
  • 2022-01-18 Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes in SCIENTIFIC REPORTS
  • 2021-10-18 Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis in NATURE COMMUNICATIONS
  • 2021-10-15 Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2021-10-04 Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia in BLOOD CANCER JOURNAL
  • 2021-09-30 Myelodysplastische Syndrome in IM FOKUS ONKOLOGIE
  • 2021-09-24 Clinico-genetic findings in 509 frontotemporal dementia patients in MOLECULAR PSYCHIATRY
  • 2021-04-27 Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) in ANNALS OF HEMATOLOGY
  • 2021-03-15 Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression in SCIENTIFIC REPORTS
  • 2021-02-19 Myelodysplastische Syndrome in BEST PRACTICE ONKOLOGIE
  • 2019-12-03 Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents in LEUKEMIA
  • 2019-08-28 Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML) in LEUKEMIA
  • 2019-04-16 Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose in EXPERIMENTAL HEMATOLOGY & ONCOLOGY
  • 2018-06-06 Erythropoiesis-Stimulating Agents in Low-Risk MDS in MYELODYSPLASTIC SYNDROMES
  • 2018-03-30 A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS in LEUKEMIA
  • 2017-10-31 Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) in ANNALS OF HEMATOLOGY
  • 2017-06-23 DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia in LEUKEMIA
  • 2017-04-03 Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial in ANNALS OF HEMATOLOGY
  • 2017-01-19 Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure in LEUKEMIA
  • 2017-01-18 Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia in LEUKEMIA
  • 2016-10-03 All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study in ANNALS OF HEMATOLOGY
  • 2016-07-04 Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group in LEUKEMIA
  • 2016-06-21 A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers in CLINICAL EPIGENETICS
  • 2016-06-13 Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity in NATURE MEDICINE
  • 2016-05-03 RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features in LEUKEMIA
  • 2015-12-15 Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) in LEUKEMIA
  • 2015-11-02 Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia in LEUKEMIA
  • 2015-07-08 Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients in LEUKEMIA
  • 2013-11-04 Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients in LEUKEMIA
  • 2013-01-28 Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study in LEUKEMIA
  • 2012-08-19 Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma in ANNALS OF HEMATOLOGY
  • 2012-07-04 Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2012-05-23 Prognose, Diagnostik und Therapie in INFO HÄMATOLOGIE + ONKOLOGIE
  • 2012-04-16 High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses in LEUKEMIA
  • 2012-01-13 Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study in LEUKEMIA
  • 2010-06-22 Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group in ANNALS OF HEMATOLOGY
  • 2008-08-12 A limited number of 5-azacitidine cycles can be effective treatment in MDS in ANNALS OF HEMATOLOGY
  • 2006-01-26 Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial in LEUKEMIA
  • 2005-04-21 High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia in LEUKEMIA
  • 2004-09-23 Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia in LEUKEMIA
  • 2002-10-01 Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors in LEUKEMIA
  • 2002-08-30 Effects of imatinib on bone marrow engraftment in syngeneic mice in LEUKEMIA
  • 2001 Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B in ACUTE LEUKEMIAS VIII
  • 2001 Stratification of Postremission Therapy in Patients with Acute Myeloid Leukemia < 60 Years According to the Karyotype: Results of the German Multicenter Treatment Trials AML HD93 and AML HD98-A in ACUTE LEUKEMIAS VIII
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.6936.a", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411937.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419842.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420057.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14778.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.15474.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.10423.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411095.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6582.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.499820.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410712.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412468.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4709.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413662.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410706.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.15090.3d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5252.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418158.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7497.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411984.1", 
            "type": "Organization"
          }
        ], 
        "familyName": "G\u00f6tze", 
        "givenName": "Katharina Simone", 
        "id": "sg:person.01320201641.22", 
        "identifier": [
          {
            "name": "orcid_id", 
            "type": "PropertyValue", 
            "value": "0000-0002-6276-8002"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320201641.22", 
          "https://orcid.org/0000-0002-6276-8002"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-09-02T16:35", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/person/person_862.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01320201641.22'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01320201641.22'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01320201641.22'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01320201641.22'


     

    This table displays all metadata directly associated to this object as RDF triples.

    59 TRIPLES      11 PREDICATES      32 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01320201641.22 schema:affiliation N9b9fec140996455a97574dc3bb365285
    2 grid-institutes:grid.10423.34
    3 grid-institutes:grid.14778.3d
    4 grid-institutes:grid.15090.3d
    5 grid-institutes:grid.15474.33
    6 grid-institutes:grid.410706.4
    7 grid-institutes:grid.410712.1
    8 grid-institutes:grid.411095.8
    9 grid-institutes:grid.411937.9
    10 grid-institutes:grid.411984.1
    11 grid-institutes:grid.412468.d
    12 grid-institutes:grid.413662.4
    13 grid-institutes:grid.418158.1
    14 grid-institutes:grid.419842.2
    15 grid-institutes:grid.420057.4
    16 grid-institutes:grid.4709.a
    17 grid-institutes:grid.499820.e
    18 grid-institutes:grid.5252.0
    19 grid-institutes:grid.6582.9
    20 grid-institutes:grid.7497.d
    21 schema:familyName Götze
    22 schema:givenName Katharina Simone
    23 schema:identifier Naaab37e30c784c92a91c8b9dcb4dc835
    24 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320201641.22
    25 https://orcid.org/0000-0002-6276-8002
    26 schema:sdDatePublished 2022-09-02T16:35
    27 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    28 schema:sdPublisher Nc7d2e306f2ec4f2c89db1dda558f6493
    29 sgo:license sg:explorer/license/
    30 sgo:sdDataset persons
    31 rdf:type schema:Person
    32 N9b9fec140996455a97574dc3bb365285 schema:affiliation grid-institutes:grid.6936.a
    33 sgo:isCurrent true
    34 rdf:type schema:OrganizationRole
    35 Naaab37e30c784c92a91c8b9dcb4dc835 schema:name orcid_id
    36 schema:value 0000-0002-6276-8002
    37 rdf:type schema:PropertyValue
    38 Nc7d2e306f2ec4f2c89db1dda558f6493 schema:name Springer Nature - SN SciGraph project
    39 rdf:type schema:Organization
    40 grid-institutes:grid.10423.34 schema:Organization
    41 grid-institutes:grid.14778.3d schema:Organization
    42 grid-institutes:grid.15090.3d schema:Organization
    43 grid-institutes:grid.15474.33 schema:Organization
    44 grid-institutes:grid.410706.4 schema:Organization
    45 grid-institutes:grid.410712.1 schema:Organization
    46 grid-institutes:grid.411095.8 schema:Organization
    47 grid-institutes:grid.411937.9 schema:Organization
    48 grid-institutes:grid.411984.1 schema:Organization
    49 grid-institutes:grid.412468.d schema:Organization
    50 grid-institutes:grid.413662.4 schema:Organization
    51 grid-institutes:grid.418158.1 schema:Organization
    52 grid-institutes:grid.419842.2 schema:Organization
    53 grid-institutes:grid.420057.4 schema:Organization
    54 grid-institutes:grid.4709.a schema:Organization
    55 grid-institutes:grid.499820.e schema:Organization
    56 grid-institutes:grid.5252.0 schema:Organization
    57 grid-institutes:grid.6582.9 schema:Organization
    58 grid-institutes:grid.6936.a schema:Organization
    59 grid-institutes:grid.7497.d schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...